GlassScriptPhysician profile
Abtin Shahlaee
NPI 1861923989
$1,857.15
in general payments reported to CMS, 2019-2025
12 companies · $47.34 in 2025
The $47.34 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $27.79 · 2022: $724 · 2023: $1,058 · 2025: $47.34.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,105.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,105.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $630.57 | 2022-2023 | Stellaris, Stellaris |
| Dutch Ophthalmic, USA | $388.77 | 2022-2023 | Tissueblue, Eva, Combined Machine |
| Alcon Vision LLC | $167.30 | 2022 | |
| Genentech, INC. | $139.46 | 2023 | Lucentis, Vabysmo |
| Genentech USA, INC. | $123.84 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $103.94 | 2022 | |
| Biogen, INC. | $95.60 | 2023 | |
| Apellis Pharmaceuticals, INC. | $83.34 | 2022 | |
| Alimera Sciences, INC. | $49.20 | 2023 | Iluvien |
| Johnson & Johnson Surgical Vision, INC. | $29.51 | 2025 | Tecnis Iol |
| Glaxosmithkline, LLC. | $27.79 | 2021 | |
| Rxsight INC | $17.83 | 2025 | Rxsight Contact Lens, Light Adjustable Lens (Lal), Rxsight Injector Cartridge |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abtin Shahlaee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.